Do Gut Hormones Contribute to Weight Loss and Glycaemic Outcomes after Bariatric Surgery?

Dimitris Papamargaritis; Carel W le Roux

doi:10.3390/nu13030762

Do Gut Hormones Contribute to Weight Loss and Glycaemic Outcomes after Bariatric Surgery?

Dimitris Papamargaritis
, Carel W le Roux

Faculty Of Life & Health Sciences

Research output: Contribution to journal › Review article › peer-review

56 Citations (Scopus)

157 Downloads (Pure)

Abstract

Bariatric surgery is an effective intervention for management of obesity through treating dysregulated appetite and achieving long-term weight loss maintenance. Moreover, significant changes in glucose homeostasis are observed after bariatric surgery including, in some cases, type 2 diabetes remission from the early postoperative period and postprandial hypoglycaemia. Levels of a number of gut hormones are dramatically increased from the early period after Roux-en-Y gastric bypass and sleeve gastrectomy-the two most commonly performed bariatric procedures-and they have been suggested as important mediators of the observed changes in eating behaviour and glucose homeostasis postoperatively. In this review, we summarise the current evidence from human studies on the alterations of gut hormones after bariatric surgery and their impact on clinical outcomes postoperatively. Studies which assess the role of gut hormones after bariatric surgery on food intake, hunger, satiety and glucose homeostasis through octreotide use (a non-specific inhibitor of gut hormone secretion) as well as with exendin 9-39 (a specific glucagon-like peptide-1 receptor antagonist) are reviewed. The potential use of gut hormones as biomarkers of successful outcomes of bariatric surgery is also evaluated.

Original language	English
Article number	762
Pages (from-to)	1-28
Number of pages	28
Journal	Nutrients
Volume	13
Issue number	3
Early online date	26 Feb 2021
DOIs	https://doi.org/10.3390/nu13030762
Publication status	Published (in print/issue) - 26 Feb 2021

Bibliographical note

Funding Information:
D.P. is funded by a National Institute of Health Research Clinical Lectureship. C.W.l.R. is funded by the Health Research Board in Ireland and the Irish Research Council. D.P. reports grants from the Novo Nordisk UK Research Foundation, the Academy of Medical Sciences and Health Education East Midlands. C.W.L.R. serves on advisory boards for Novo Nordisk, Boehringer Ingelheim, Herbalife, GI Dynamics, Keyron, and Johnson&Johnson.

Funding Information:
Acknowledgments: D.P. is funded by a National Institute of Health Research Clinical Lectureship. C.W.l.R. is funded by the Health Research Board in Ireland and the Irish Research Council.

Funding Information:
Conflicts of Interest: D.P. reports grants from the Novo Nordisk UK Research Foundation, the Academy of Medical Sciences and Health Education East Midlands. C.W.L.R. serves on advisory boards for Novo Nordisk, Boehringer Ingelheim, Herbalife, GI Dynamics, Keyron, and Johnson&Johnson.

Publisher Copyright:
© 2021 by the authors. Licensee MDPI, Basel, Switzerland.

Funding

Funding Information: D.P. is funded by a National Institute of Health Research Clinical Lectureship. C.W.l.R. is funded by the Health Research Board in Ireland and the Irish Research Council. D.P. reports grants from the Novo Nordisk UK Research Foundation, the Academy of Medical Sciences and Health Education East Midlands. C.W.L.R. serves on advisory boards for Novo Nordisk, Boehringer Ingelheim, Herbalife, GI Dynamics, Keyron, and Johnson&Johnson. Funding Information: Acknowledgments: D.P. is funded by a National Institute of Health Research Clinical Lectureship. C.W.l.R. is funded by the Health Research Board in Ireland and the Irish Research Council. Funding Information: Conflicts of Interest: D.P. reports grants from the Novo Nordisk UK Research Foundation, the Academy of Medical Sciences and Health Education East Midlands. C.W.L.R. serves on advisory boards for Novo Nordisk, Boehringer Ingelheim, Herbalife, GI Dynamics, Keyron, and Johnson&Johnson. Publisher Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

GLP-1
PYY
Roux-en-Y gastric bypass
bariatric surgery
gastric band
ghrelin
gut hormones
sleeve gastrectomy

Access to Document

10.3390/nu13030762

nutrients-13-00762-v3Final published version, 913 KBLicence: CC BY

Cite this

@article{9086b2c9a9d047b7a6d760b63f17f993,

title = "Do Gut Hormones Contribute to Weight Loss and Glycaemic Outcomes after Bariatric Surgery?",

abstract = "Bariatric surgery is an effective intervention for management of obesity through treating dysregulated appetite and achieving long-term weight loss maintenance. Moreover, significant changes in glucose homeostasis are observed after bariatric surgery including, in some cases, type 2 diabetes remission from the early postoperative period and postprandial hypoglycaemia. Levels of a number of gut hormones are dramatically increased from the early period after Roux-en-Y gastric bypass and sleeve gastrectomy-the two most commonly performed bariatric procedures-and they have been suggested as important mediators of the observed changes in eating behaviour and glucose homeostasis postoperatively. In this review, we summarise the current evidence from human studies on the alterations of gut hormones after bariatric surgery and their impact on clinical outcomes postoperatively. Studies which assess the role of gut hormones after bariatric surgery on food intake, hunger, satiety and glucose homeostasis through octreotide use (a non-specific inhibitor of gut hormone secretion) as well as with exendin 9-39 (a specific glucagon-like peptide-1 receptor antagonist) are reviewed. The potential use of gut hormones as biomarkers of successful outcomes of bariatric surgery is also evaluated.",

keywords = "GLP-1, PYY, Roux-en-Y gastric bypass, bariatric surgery, gastric band, ghrelin, gut hormones, sleeve gastrectomy",

author = "Dimitris Papamargaritis and \{le Roux\}, \{Carel W\}",

note = "Funding Information: D.P. is funded by a National Institute of Health Research Clinical Lectureship. C.W.l.R. is funded by the Health Research Board in Ireland and the Irish Research Council. D.P. reports grants from the Novo Nordisk UK Research Foundation, the Academy of Medical Sciences and Health Education East Midlands. C.W.L.R. serves on advisory boards for Novo Nordisk, Boehringer Ingelheim, Herbalife, GI Dynamics, Keyron, and Johnson\&Johnson. Funding Information: Acknowledgments: D.P. is funded by a National Institute of Health Research Clinical Lectureship. C.W.l.R. is funded by the Health Research Board in Ireland and the Irish Research Council. Funding Information: Conflicts of Interest: D.P. reports grants from the Novo Nordisk UK Research Foundation, the Academy of Medical Sciences and Health Education East Midlands. C.W.L.R. serves on advisory boards for Novo Nordisk, Boehringer Ingelheim, Herbalife, GI Dynamics, Keyron, and Johnson\&Johnson. Publisher Copyright: {\textcopyright} 2021 by the authors. Licensee MDPI, Basel, Switzerland.",

year = "2021",

month = feb,

day = "26",

doi = "10.3390/nu13030762",

language = "English",

volume = "13",

pages = "1--28",

journal = "Nutrients",

issn = "2072-6643",